[Value of angiogenesis inhibitors in tumor diseases--preclinical data]].
Berdel
Wolfgang E
WE
Medizinische Klinik A, Universitätsklinikum Münster, Münster, Germany.
Panse
Jens
J
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D009361:Neoplasm Invasiveness; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D017479:Receptors, Platelet-Derived Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor